Recent Updates
Recently added Catalysts
KRYS

Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference

Key Takeaway: PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Ca
Price reaction · baseline $57.74 (2022-02-23 close) · hit after-hours · 1 other KRYS headline(s) in the window, move may be shared
day 0 close
+5.3%
day 1
+8.2%
day 3 · peak
+11.1%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+100%
120-day peak, hindsight
Typical move
4.2%
average across 5 past catalysts
Lead asset
KB707
Phase 1 · Cancer

Full Press Release Details

PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference, which is taking place virtually March 7-9, 2022.
Details are as follows:
Fireside Chat Date: Monday, March 7, 2022
Fireside Chat Time: 2:50-3:20 p.m. EST
Webcast link: https://wsw.com/webcast/cowen108/krys/2056797
A webcast of the presentation will be available for 90 days and can be found on the Krystal Biotech website at http://ir.krystalbio.com/events-and-presentations/events.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to potentially bring life-changing treatment options to patients with serious diseases, including rare diseases in skin, lung and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.
Last updated: Feb 24, 2022